Skip to main content

Advertisement

SpringerLink
Log in

Optimising drug therapy for non-infectious uveitis

  • Review
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Introduction

Uveitis encompasses a wide variety of sight-threatening diseases characterized by intraocular inflammation. It is often classified as infectious and non-infectious uveitis. Unlike infectious uveitis, a distinct infectious agent cannot be identified in non-infectious uveitis and disease origin is usually autoimmune, drug related, or idiopathic.

The Issue at Hand

Non-infectious uveitis can often have a relapsing-remitting course, making it difficult to treat, and poses a significant challenge to ophthalmologists. The autoimmune nature of non-infectious uveitis warrants the use of anti-inflammatory and immunomodulatory agents for disease control. However, a subset of patients has persistent or recurrent ocular inflammation despite appropriate treatment, stressing the need for newer therapies aimed at more specific inflammatory targets such as tumour necrosis factor (TNF) alpha agents, anti-interleukin agents, and anti-interleukin receptor agents.

Objectives

This article discusses the various medical options available for the treatment of non-infectious uveitis in the light of the most recent evidence.

Conclusion

Successful management of non-infectious uveitis requires the clinician carefully balance advantages and disadvantages of each new and old therapy while considering individual circumstances. Counselling regarding the benefits and complications of each therapy can help patients make an informed choice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Keino H, Watanabe T, Taki W, Nakayama M, Nakamura T, Yan K et al (2017) Clinical features of uveitis in children and adolescents at a tertiary referral centre in Tokyo. Br J Ophthalmol 101(4):406–410

    Article  PubMed  Google Scholar 

  2. Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14(5–6):303–308

    Article  CAS  PubMed  Google Scholar 

  3. Kollias G, Kontoyiannis D (2002) Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13(4–5):315–321

    Article  CAS  PubMed  Google Scholar 

  4. Poetker DM, Reh DD (2010) A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 43(4):753–768

    Article  PubMed  Google Scholar 

  5. McGhee CN (1992) Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol 76(11):681–684

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chambers WA. FDA Approval Letter for Triesence 2007. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022048s000,%20022223s000ltr.pdf

  7. Liu X, Wang M, Zhao C, Gao F, Zhang M (2015) The efficacy and safety of subconjunctival triamcinolone acetonide injections in treatment of uveitic macular edema. Zhonghua Yan Ke Za Zhi 51(10):734–738

    PubMed  Google Scholar 

  8. Bleriot A, Couret C, Le Meur G, Lebranchu P, Weber M (2014) Safety and efficacy of subconjunctival triamcinolone injections in the management of uveitic macular edema: retrospective study of thirty-one cases. J Fr Ophtalmol 37(8):599–604

    Article  CAS  PubMed  Google Scholar 

  9. Sen HN, Vitale S, Gangaputra SS, Nussenblatt RB, Liesegang TL, Levy-Clarke GA et al (2014) Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 121(11):2275–2286

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mir TA, Reddy A (2016) Inside the Uveitis Toolbox. Retina Today 2016:33–35

    Google Scholar 

  11. Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A (2009) Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 42(2):81–86

    Article  CAS  PubMed  Google Scholar 

  12. Zarranz-Ventura J, Carreno E, Johnston RL, Mohammed Q, Ross AH, Barker C et al (2014) Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol 158(6):1136–1145

    Article  CAS  PubMed  Google Scholar 

  13. FDA. Approval Letter for Retisert 2005. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021737s000_APPROV.pdf

  14. Sangwan VS, Pearson PA, Paul H, Comstock TL (2015) Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther 4(1):1–19

    Article  PubMed  Google Scholar 

  15. Arcinue CA, Ceron OM, Foster CS (2013) A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 29(5):501–507

    Article  CAS  PubMed  Google Scholar 

  16. Kane FE, Burdan J, Cutino A, Green KE (2008) Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 5(9):1039–1046

    Article  CAS  PubMed  Google Scholar 

  17. ClinicalTrials.gov. Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis (Iluvien) 2012. https://clinicaltrials.gov/ct2/show/NCT01781936

  18. Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA et al (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116(11):2188–2198

    Article  PubMed  PubMed Central  Google Scholar 

  19. Samson CM, Waheed N, Baltatzis S, Foster CS (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108(6):1134–1139

    Article  CAS  PubMed  Google Scholar 

  20. Kremer JM, Alarcón GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ et al (1994) Methotrexate for rheumatoid arthritis. Arthritis Rheum 37(3):316–328

    Article  CAS  PubMed  Google Scholar 

  21. Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters GB 3rd et al (2008) Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115(10):1826–1832

    Article  PubMed  Google Scholar 

  22. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA et al (2010) Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 149(3):423–432

    Article  CAS  PubMed  Google Scholar 

  23. Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112(8):1472–1477

    Article  PubMed  Google Scholar 

  24. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT et al (2009) Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148(4):500–509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Özyazgan Y, Silman A et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322(5):281–285

    Article  CAS  PubMed  Google Scholar 

  26. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB et al (2010) Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117(2):356–365

    Article  PubMed  Google Scholar 

  27. Chung JB, Armstrong K, Schwartz JS, Albert D (2000) Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43(8):1841–1848

    Article  CAS  PubMed  Google Scholar 

  28. Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB et al (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117(3):576–584

    Article  PubMed  PubMed Central  Google Scholar 

  29. Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I (2008) Cyclosporine for Behcet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26(4 Suppl 50):S84–S90

    CAS  PubMed  Google Scholar 

  30. Gijtenbeek JM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246(5):339–346

    Article  CAS  PubMed  Google Scholar 

  31. Kilmartin DJ, Forrester JV, Dick AD (1998) Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6(2):101–109

    Article  CAS  PubMed  Google Scholar 

  32. Mochizuki M, Masuda K, Sakane T, Ito K, Kogure M, Sugino N et al (1993) A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115(6):763–769

    Article  CAS  PubMed  Google Scholar 

  33. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123(5):634–641

    Article  CAS  PubMed  Google Scholar 

  34. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW et al (1999) A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transp 18(4):336–345

    Article  CAS  Google Scholar 

  35. Diaz-Llopis M, Garcia-Delpech S, Salom D, Udaondo P, Hernandez-Garfella M, Bosch-Morell F et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351–361

    Article  CAS  PubMed  Google Scholar 

  36. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701

    Article  CAS  PubMed  Google Scholar 

  37. Bawazeer A, Raffa LH, Nizamuddin (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 18(3):226–232

    Article  CAS  PubMed  Google Scholar 

  38. Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 97(4):481–486

    Article  PubMed  Google Scholar 

  39. Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT (2014) Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 66(7):1073–1084

    Article  CAS  Google Scholar 

  40. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932–943

    Article  CAS  PubMed  Google Scholar 

  41. Brezin AP, Kestelyn P, Van Calster J, Jaffe GJ, Thorne JE, Scales D, Franco P, Dick AD, Nguyen QD, Suhler EB, Camez A, Song AP, Kron M, Tari S, Rosenbaum JT, Heiligenhaus A (2015 ) Adalimumab in patients with active, noninfectious uveitis using high-dose corticosteroids [abstract] 67(suppl 10). http://acrabstracts.org/abstract/adalimumab-in-patients-with-active-noninfectious-uveitis-using-high-dose-corticosteroids/

  42. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192

    Article  CAS  PubMed  Google Scholar 

  43. AbbVie’s HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis 2016. https://news.abbvie.com/news/abbvies-humira-adalimumab-receives-us-food-and-drug-administration-approval-to-treat-adults-with-non-infectious-intermediate-posterior-and-panuveitis.htm

  44. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM (2013) Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72(4):517–524

    Article  CAS  PubMed  Google Scholar 

  45. Abbvie. Humira Prescribing Information 2016. http://www.rxabbvie.com/pdf/humira.pdf

  46. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 358(9278):295–296

    Article  CAS  PubMed  Google Scholar 

  47. Markomichelakis N, Delicha E, Masselos S, Sfikakis PP (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol 154(3):534–541

    Article  CAS  PubMed  Google Scholar 

  48. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP (2011) A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet’s disease: a comparative 4-week study. Rheumatology 50(3):593–597

    Article  CAS  PubMed  Google Scholar 

  49. Suhler EB, Smith JR, Wertheim MS et al (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123(7):903–912

    Article  CAS  PubMed  Google Scholar 

  50. Tabbara KF, Al-Hemidan AI (2008) Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol 146(6):845–850

    Article  CAS  PubMed  Google Scholar 

  51. Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L et al (2016) Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 68(6):1522–1530

    Article  CAS  PubMed  Google Scholar 

  52. Pasadhika S, Rosenbaum JT (2014) Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther 8:67–81

    Google Scholar 

  53. Dogra S, Khullar G (2013) Tumor necrosis factor-alpha antagonists: side effects and their management. Indian J Dermatol Venereol Leprol 79(Suppl 7):S35–S46

    Article  PubMed  Google Scholar 

  54. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B et al (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44(6):1411–1415

    Article  CAS  PubMed  Google Scholar 

  55. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121(4):437–440

    Article  CAS  PubMed  Google Scholar 

  56. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(3):785–796

    Article  PubMed  Google Scholar 

  57. Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113(12):2317–2323

    Article  PubMed  Google Scholar 

  58. Calvo-Rio V, de la Hera D, Blanco R, Beltran-Catalan E, Loricera J, Canal J et al (2014) Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol 32(6):864–868

    PubMed  Google Scholar 

  59. Faez S, Lobo AM, Sobrin L, Papaliodis GN (2014) Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Exp Ophthalmol 42(4):392–395

    Article  PubMed  Google Scholar 

  60. Cordero-Coma M, Salom D, Díaz-Llopis M, López-Prats MJ, Calleja S (2011) Golimumab for uveitis. Ophthalmology 118(9):1892

    Article  PubMed  Google Scholar 

  61. William M, Faez S, Papaliodis GN, Lobo A-M (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthal Inflamm Infect 2(4):231–233

    Article  Google Scholar 

  62. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V (2014) Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 22(2):90–95

    Article  CAS  PubMed  Google Scholar 

  63. Santos-Gomez M, Calvo-Rio V, Blanco R, Beltran E, Mesquida M, Adan A et al (2016) The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol 34(6 Suppl 102):S34–S40

    PubMed  Google Scholar 

  64. Michelon MA, Gottlieb AB (2010) Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis. Clin Cosmet Investig Dermatol CCID 3:79–84

    CAS  PubMed  Google Scholar 

  65. Tappeiner C, Miserocchi E, Bodaghi B, Kotaniemi K, Mackensen F, Gerloni V et al (2015) Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 42(4):706–711

    Article  CAS  PubMed  Google Scholar 

  66. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA et al (2013) Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res 65(3):476–480

    Article  CAS  Google Scholar 

  67. Tomkins-Netzer O, Taylor SR, Lightman S (2013) Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation? Ophthalmologica 230(3):109–115

    Article  CAS  PubMed  Google Scholar 

  68. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A et al (2010) Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13(3):246–252

    Article  PubMed  Google Scholar 

  69. Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V (2016) Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 100(6):782–786

    Article  PubMed  Google Scholar 

  70. Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS (2012) Clinical review: Serious adverse events associated with the use of rituximab—a critical care perspective. Crit Care 16(4):231

    Article  PubMed  PubMed Central  Google Scholar 

  71. Hasanreisoglu M, Cubuk MO, Ozdek S, Gurelik G, Aktas Z, Hasanreisoglu B (2017) Interferon Alpha-2a therapy in patients with refractory Behcet uveitis. Ocul Immunol Inflamm 25(1):71–75

    Article  CAS  PubMed  Google Scholar 

  72. Kotter I, Gunaydin I, Zierhut M, Stubiger N (2004) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33(5):320–335

    Article  CAS  PubMed  Google Scholar 

  73. ClinicalTrials.gov. Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a (BIRDFERON). https://clinicaltrials.gov/ct2/show/NCT00508040

  74. Rosenbaum JT, Boney RS (1992) ACtivity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol 110(4):547–549

    Article  CAS  PubMed  Google Scholar 

  75. Arida A, Sfikakis PP (2014) Anti-cytokine biologic treatment beyond anti-TNF in Behcet’s disease. Clin Exp Rheumatol 32(4 Suppl 84):149–155

    Google Scholar 

  76. Teoh SCB, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91(2):263–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R et al (2015) Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol 34(7):1293–1301

    Article  PubMed  Google Scholar 

  78. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787

    Article  PubMed  Google Scholar 

  79. Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL (2015) Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 122(5):939–948

    Article  PubMed  Google Scholar 

  80. News GEaB. Xoma’s Gevokizumab Fails Phase III Trial 2015. http://www.genengnews.com/gen-news-highlights/xoma-s-gevokizumab-fails-phase-iii-trial/81251535/

  81. Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, Lee SCMP, Ozdal P, Ozyazgan Y et al (2017) Safety and efficacy of gevokizumab in patients with Behcet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm 25(1):62–70

    Article  CAS  Google Scholar 

  82. Bhat P, Castaneda-Cervantes RA, Doctor PP, Foster CS (2009) Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 247(5):687–692

    Article  CAS  PubMed  Google Scholar 

  83. Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764–770

    Article  PubMed  Google Scholar 

  84. Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s disease. Ocul Immunol Inflamm 15(2):63–70

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, noninfectious uveitis. J Autoimmun 31(2):91–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Wroblewski K, Sen HN, Yeh S, Faia L, Li Z, Sran P et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol J 46(4):322–328

    Article  Google Scholar 

  87. Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–1295

    Article  PubMed  Google Scholar 

  88. Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P et al (2014) Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol 32(4 Suppl 84):S75–S79

    PubMed  Google Scholar 

  89. Calvo-Rio V, de la Hera D, Beltran-Catalan E, Blanco R, Hernandez M, Martinez-Costa L et al (2014) Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 32(4 Suppl 84):S54–S57

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aga Khan University, Karachi, Pakistan

    Mohammad Ali Shahab & Sidra Zafar

  2. Johns Hopkins Wilmer Eye Institute, Baltimore, USA

    Tahreem Aman Mir

Authors
  1. Mohammad Ali Shahab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tahreem Aman Mir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sidra Zafar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Ali Shahab.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors. Therefore, no informed consent was necessary.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shahab, M.A., Mir, T.A. & Zafar, S. Optimising drug therapy for non-infectious uveitis. Int Ophthalmol 39, 1633–1650 (2019). https://doi.org/10.1007/s10792-018-0984-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-018-0984-1

Keywords

Search

Navigation